[Cryotherapy for prostate cancer].

Area of Science:

• Urology
• Oncology

Background:

• Prostate cancer is a significant health concern.
• Cryotherapy presents a minimally invasive treatment option.

Purpose of the Study:

• To evaluate the efficacy of cryotherapy for localized prostate cancer.
• To assess post-treatment prostate-specific antigen (PSA) levels and patient outcomes.

Main Methods:

• Cryotherapy was performed on 40 patients with localized prostate cancer between September 2003 and January 2005.
• Patients were stratified based on tumor characteristics (T1-2), Gleason score (<7 or >=7), and PSA levels (<10 ng/ml or >=10 ng/ml).
• PSA levels were measured at 3 months post-treatment.

Main Results:

• Patients with lower-risk disease (T1-2, Gleason <7, PSA <10 ng/ml) showed an average PSA of 0.32 ng/ml after 3 months.
• Patients with higher-risk disease (T1-2, Gleason >=7 or PSA >=10 ng/ml) had an average PSA of 0.56 ng/ml after 3 months.
• All patients experienced normal micturition after 3 months, with no palpable prostate tissue detected.

Conclusions:

• Cryotherapy is an effective treatment for localized prostate cancer.
• The procedure demonstrates favorable short-term outcomes, including significant PSA reduction and normal urinary function.
• The results are comparable to international findings, suggesting cryotherapy's viability in clinical practice.